达格列净对控制不佳的1型糖尿病患者的疗效与安全性(DEPICT-1):一项多中心、双盲、3期随机对照试验的24周结果
DEPICT-1是在17个国家143个中心开展的双盲、随机、平行对照、三臂3期研究,纳入833例血糖控制不佳的1型糖尿病患者(HbA1c≥7.7%且≤11.0%),随机接受达格列净5 mg、10 mg或安慰剂。24周时,达格列净5 mg和10 mg较安慰剂均显著降低HbA1c,平均差异分别为-0.42%和-0.45%;低血糖和严重低血糖发生率组间相似,达格列净组发生判定明确的糖尿病酮症酸中毒4例(5 mg组)和5例(10 mg组),安慰剂组3例。
要点
- 24周时达格列净5 mg和10 mg较安慰剂显著降低HbA1c,平均差异分别为-0.42%和-0.45%。
- 低血糖发生率三组分别为79%、79%和80%,严重低血糖分别为8%、6%和7%。
- 判定明确的糖尿病酮症酸中毒在达格列净5 mg组4例(1%)、10 mg组5例(2%)、安慰剂组3例(1%)。
核心结论
- 结果提示达格列净作为胰岛素的辅助治疗,对改善控制不佳的1型糖尿病患者的血糖控制是有前景的。
研究设计与样本
- DEPICT-1为双盲、随机、平行对照、三臂、3期多中心研究,在17个国家的143个中心开展。
- 纳入18-75岁、HbA1c≥7.7%且≤11.0%(≥61.0 mmol/mol且≤97.0 mmol/mol)、入组前已处方胰岛素至少12个月的控制不佳1型糖尿病患者。
- 经8周导入期优化糖尿病管理后,按1:1:1随机分配至达格列净5 mg或10 mg每日一次口服或匹配安慰剂,随机化按当前持续葡萄糖监测使用、胰岛素给药方式和基线HbA1c分层。
- 833例患者被分配至治疗组并纳入安全性分析(达格列净5 mg n=277 vs 10 mg n=296 vs 安慰剂 n=260);778例被随机分配并纳入全分析集进行疗效分析(259 vs 259 vs 260),差异源于影响55例患者的随机化错误。
- 主要疗效结局为治疗24周后全分析集中HbA1c自基线的变化;研究注册号NCT02268214,本分析数据收集于2017年1月4日完成,28周扩展期正在进行。
主要发现
- 基线平均HbA1c为8.53%(70 mmol/mol;SD 0.67%[7.3 mmol/mol])。
- 第24周时,达格列净5 mg较安慰剂自基线至第24周的平均差异为-0.42%(95%CI -0.56至-0.28;p<0.0001),达格列净10 mg较安慰剂为-0.45%(95%CI -0.58至-0.31;p<0.0001)。
- 达格列净5 mg组(n=277)、10 mg组(n=296)和安慰剂组(n=260)最常见的不良事件分别为鼻咽炎38例(14%)vs 36例(12%)vs 39例(15%)、尿路感染19例(7%)vs 11例(4%)vs 13例(5%)、上呼吸道感染15例(5%)vs 15例(5%)vs 11例(4%)、头痛12例(4%)vs 17例(6%)vs 11例(4%)。
- 低血糖发生率在达格列净5 mg、10 mg和安慰剂组分别为220例(79%)、235例(79%)和207例(80%);严重低血糖分别为21例(8%)、19例(6%)和19例(7%)。
- 判定明确的糖尿病酮症酸中毒在达格列净5 mg组4例(1%)、10 mg组5例(2%)、安慰剂组3例(1%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor approved for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of dapagliflozin as an add-on to adjustable insulin in patients with inadequately controlled type 1 diabetes. METHODS: DEPICT-1 was a double-blind, randomised, parallel-controlled, three-arm, phase 3, multicentre study done at 143 sites in 17 countries. Eligible patients were aged 18-75 years and had inadequately controlled type 1 diabetes (HbA1c between ≥7·7% and ≤11·0% [≥61·0 mmol/mol and ≤97·0 mmol/mol]) and had been prescribed insulin for at least 12 months before enrolment. After an 8 week lead-in period to optimise diabetes management, patients were randomly assigned (1:1:1) using an interactive voice response system to dapagliflozin 5 mg or 10 mg once daily, given orally, or matched placebo. Randomisation was stratified by current use of continuous glucose monitoring, method of insulin administration, and baseline HbA1c. The primary efficacy outcome was the change from baseline in HbA1c after 24 weeks of treatment in the full analysis set, which consisted of all randomly assigned patients who received at least one dose of study drug. An additional 55 patients who were incorrectly and non-randomly allocated to only dapagliflozin treatment groups were included in the safety analysis set. This study was registered with ClinicalTrials.gov, number NCT02268214; data collection for the present analysis was completed on Jan 4, 2017, and a 28 week extension phase is ongoing. FINDINGS: Between Nov 11, 2014, and April 16, 2016, 833 patients were assigned to treatment groups and included in safety analyses (dapagliflozin 5 mg [n=277] vs dapagliflozin 10 mg [n=296] vs placebo [n=260]; 778 of these patients were randomly assigned and included in the full analysis set for efficacy analyses (259 vs 259 vs 260; difference due to randomisation error affecting 55 patients). Mean baseline HbA1c was 8·53% (70 mmol/mol; SD 0·67% [7·3 mmol/mol]). At week 24, both doses of dapagliflozin significantly reduced HbA1c compared with placebo (mean difference from baseline to week 24 for dapagliflozin 5 mg vs placebo was -0·42% [95% CI -0·56 to -0·28; p<0·0001] and for dapagliflozin 10 mg vs placebo was -0·45% [-0·58 to -0·31; p<0·0001]). Among patients in the dapagliflozin 5 mg (n=277), dapagliflozin 10 mg (n=296), and placebo (n=260) groups, the most common adverse events were nasopharyngitis (38 [14%] vs 36 [12%] vs 39 [15%]), urinary tract infection (19 [7%] vs 11 [4%] vs 13 [5%]), upper respiratory tract infection (15 [5%] vs 15 [5%] vs 11 [4%]), and headache (12 [4%] vs 17 [6%] vs 11 [4%]). Hypoglycaemia occurred in 220 (79%), 235 (79%), and 207 (80%) patients in the dapagliflozin 5 mg, dapagliflozin 10 mg, and placebo groups, respectively; severe hypoglycaemia occurred in 21 (8%), 19 (6%), and 19 (7%) patients, respectively. Adjudicated definite diabetic ketoacidosis occurred in four (1%) patients in the dapagliflozin 5 mg group, five (2%) in the dapagliflozin 10 mg group, and three (1%) in the placebo group. INTERPRETATION: Our results suggest that dapagliflozin is a promising adjunct treatment to insulin to improve glycaemic control in patients with inadequately controlled type 1 diabetes. FUNDING: AstraZeneca and Bristol-Myers Squibb.
引用
- Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017. PMID: 28919061. doi:10.1016/S2213-8587(17)30308-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。